Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

Interim results from a National Institutes of Health (NIH)-supported clinical trial of the Bavarian Nordic mpox vaccine ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 ...

After approving Bavarian Nordic’s mpox vaccine in September for use in adults, the World Health Organisation has given the ...

With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, ...

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in ...

Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpoxThe World Health ...

Two recent studies indicate that the efficacy of Bavarian Nordic’s vaccine against Mpox diminishes to undetectable levels within 6 to 12 months. This discovery raises concerns about long-term ...

The World Health Organization approved the use of Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, ...

Interim results of a phase 2 trial indicate that the mpox vaccine MVA-VN has an immune response in adolescents similar to ...

The World Health Organization has approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17, a group considered ...

WHO has approved Bavarian Nordic's mpox vaccine for adolescents, expanding access as global concern over the viral outbreak ...